title: The Canadian Association of Interventional Cardiology and the Canadian Cardiovascular Society joint statement on drug-eluting stents.
abstract: Recent reports of late stent thrombosis events following deployment of drug-eluting stents (DES) have raised concerns about their safety and role in the management of coronary artery disease. The Canadian Association of Interventional Cardiology and the Canadian Cardiovascular Society have carefully examined the available evidence, including the data presented at the recent Food and Drug Administration Circulatory System Devices Advisory Panel meeting. The purpose of the present statement is to summarize the available evidence relating to DES thrombosis and to provide practical recommendations regarding DES use and antiplatelet therapy.
authors.affiliation: Division of Cardiology, Queen Elizabeth II Health Sciences Centre, Halifax, Nova Scotia. michael.love@cdha.nshealth.ca
authors.forename: Machael P
authors.initials: MP
authors.lastname: Love
authors.forename: Erick
authors.initials: E
authors.lastname: Schampaert
authors.forename: Eric A
authors.initials: EA
authors.lastname: Cohen
authors.forename: John G
authors.initials: JG
authors.lastname: Webb
authors.forename: Todd J
authors.initials: TJ
authors.lastname: Anderson
authors.forename: Marino
authors.initials: M
authors.lastname: Labinaz
authors.forename: Jean-François
authors.initials: JF
authors.lastname: Tanguay
authors.forename: Vladimír
authors.initials: V
authors.lastname: Dzavík
mesh_terms: D004334:Drug Administration Schedule; D006083:Graft Occlusion, Vascular / Q000209:etiology / Q000517:prevention & control*; D006801:Humans; D018579:Patient Selection; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage*; D012307:Risk Factors; D015607:Stents / Q000009:adverse effects
chemical_list: D010975:Platelet Aggregation Inhibitors